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1. Introduction
In mammals, the matrix of the mitochondria is the
site of many fundamental energy transducing reac-
tions. The inner membrane is essentially a selectively
permeable membrane. Hence speci¢c transporters ex-
ist in the inner membrane to provide access for ions
that regulate mitochondrial physiology and metabo-
lism and to provide access for substrates linking met-
abolic and replication processes compartmentalised
within the mitochondrial matrix to other cellular
processes. Modulation of or mutations in these trans-
porters have e¡ects on whole body physiology and
pathology [1^3].
Transport studies on isolated mitochondria from
various mammalian tissues have led to the character-
isation thus far of approximately 25 distinguishable
inner membrane transport systems [4^7]. Many have
been puri¢ed to varying degrees and some have been
cloned [8,9]. Notable features of the cloned trans-
porters include (i) a recurrent tripartite amino acid
motif (P-X-[D/E]-X-[L/V/I/A/T]-X-[L/R/H]-[L/I/V/M/
F/Y]); (ii) similar length protein (V300 amino
acids); and (iii) six putative transmembrane K-helices
(2 pair 100 amino acid). Indeed, the recurrent motif
has been used to de¢ne mitochondrial transporter
family. In addition, some of the sequences cloned
have yet to have their protein function established
[10,11]. In yeast, there are V32 sequences with the
‘mitochondrial family’ motif. Some of these trans-
porter clones have been characterised and the trans-
porter function has been shown to be identical to
those in mammalian mitochondria. Other yeast
transporter clones have been useful in detecting novel
mammalian mitochondrial transporter function,
although not all mammalian mitochondrial trans-
porter will have equivalents in yeast.
A summary of the mitochondrial cationic and neu-
tral amino acid (and modi¢ed amino acid) transport
systems, that have been characterised in mammals, is
given in this review.
2. Amino acid transporters
2.1. Neutral amino acids in general
Non-respiring mitochondria swell when suspended
in isotonic solutions of each of several di¡erent ami-
no acids, indicating that these compounds can pene-
trate the mitochondrial inner membrane [5,6]. Gam-
ble and Lehninger [12] showed that rat liver
mitochondria swell in glycine, alanine, proline, valine
and citrulline, but rat heart mitochondria do not
swell in citrulline. Halling et al. [13] also showed
that a variety of neutral amino acids, including
non-metabolisable amino acids, could penetrate the
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mitochondrial inner membrane and suggested that
the ability of amino acids to form ring structures
as a result of intra-molecular hydrogen bonding
may be important in their permeation through the
membrane. Brand and Chappell [14] demonstrated
that the initial swelling rate of rat liver and brain
mitochondria was a linear function of external Q-ami-
nobutyric acid concentration, suggesting that this
neutral amino acid di¡uses across the inner mem-
brane.
Further advances were made when Cybulski and
Fisher [15] found that mitochondrial swelling in neu-
tral amino acids showed L-stereoisomer speci¢city.
Furthermore, diazobenzenesulphonate, a reagent
that reacts with amino group residues on proteins,
strongly inhibited swelling in solutions of glycine and
L-isomers of alanine, cysteine, leucine, methionine,
proline, serine, threonine and valine but did not in-
hibit the transport of compounds such as acetate or
thiocyanate which enter the matrix space by di¡u-
sion. In addition p-chloromercuribenzoate, a sul-
phydryl reagent, also inhibited swelling and it was
also shown that several of the amino acids mutually
protect against inhibition by these reagents when
present in the preincubation mixture. High proline
concentrations did not however protect against its
own transport or against transport of other neutral
amino acids. But for the other amino acids the re-
sults suggested that a single carrier existed with
rather broad speci¢city. Although the majority of
neutral amino acids did not require energy or iono-
phores for swelling, it seems that proline uptake may
be linked to an energy-dependent, as yet unidenti¢ed,
cation transporter [16]. A proline/glutamate antiport
in rat kidney mitochondria has been characterised
[17]. Movement across the mitochondrial membrane
suggest that the proline/glutamate antiporter is driv-
en by v8.
2.2. Glycine transport
Benavides et al. [18] have gone some way to char-
acterising glycine uptake in rat brain and liver mito-
chondria. They have shown that glycine transport in
brain has a Km of 1.7 mM and that of liver mito-
chondria has a Km of 5.7 mM. Uptake is reported to
be inhibited by methylmalonate, propionate, phos-
phoserine and mersalyl (at pH 6.5).
2.3. Glutamine transport
The proximal tubule cell is the major site of renal
ammoniagenesis and glutamine is the major sub-
strate. Deamidation by mitochondrial glutaminase
yields glutamate- and NH4 . A second NH

4 ion is
obtained by deamination of glutamate- to 2-oxo-glu-
tarate [6].
Kinetics of mitochondrial glutamine transport
have been studied [19]. Glutamine concentration at
half-maximal velocity (S0:5) was 9.07 and 13.3 mM
at pH 6.5 and 8.5, respectively. The Vmax was
1418 þ 186 pmol mg31 15 s31 at pH 6.5 and
911 þ 193 pmol mg31 15 s31 at pH 8.5. Thus both
the a⁄nity and the Vmax of the transport system
were enhanced in acidic pH. The uptake of
[3H]glutamine in submitochondrial particles was
also measured at varying medium pH. Glutamine
transport was inversely related to medium pH (range
6.5^8.5). Glutamine uptake was highest at medium
pH of 6.5 (4.6 þ 0.4 pmol mg31 30 s31) and lowest at
medium pH of 8.0 (2.0 þ 0.3 pmol mg31 30 s31).
The glutamine carrier from rat kidney mitochon-
dria has been puri¢ed. The carrier consists of a single
protein band with an apparent molecular mass of
41.5 kDa [20]. When reconstituted into liposomes,
the glutamine carrier catalysed both the unidirection-
al £ux of glutamine and the glutamine/glutamine
countertransport. Transport was completely inhibit-
able by a mixture of pyridoxal 5P-phosphate and N-
ethylmaleimide and several other thiol- and amino-
group reagents.
A glutamine transporter has also been character-
ised in mitochondrial-inner-membrane vesicles, iso-
lated from Ehrlich ascites carcinoma cells [21]. Con-
veniently, the vesicles lack any phosphate-activated
glutaminase activity, allowing measurement of trans-
port rates without interference by L-glutamine me-
tabolism. L-Glutamine transport showed co-operativ-
ity, with a Hill coe⁄cient of 2.2; the kinetic
parameters S0:5 and Vmax had values of 5 mM and
26 nmol/30 s per mg of protein, respectively, the pH
optimum being about 8.0. The uptake of L-glutamine
was not a¡ected by the presence of excess D-gluta-
mine, L-cysteine, L-histidine, L-alanine, L-serine and
L-leucine, whereas L-glutamate behaved as a weak
inhibitor. A structural analogue, L-glutamate Q-hy-
droxamate (5 mM), inhibited the uptake by 68%.
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Other analogues (6-diazo-5-oxo-L-norleucine, acivi-
cin and L-glutamate gamma-hydrazide) were ine¡ec-
tive. The thiol reagent p-chloromercuriphenylsul-
phonic acid (0.5 mM) completely abolished the
mitochondrial L-glutamine uptake; by contrast, other
thiol reagents (mersalyl and N-ethylmaleimide) did
not signi¢cantly a¡ect the transport.
A glutamine transport system has been described
in liver [22]. Glutamine is taken up by rat liver mi-
tochondria in an electroneutral manner with a Km of
3.3 mM and a Vmax of 33 nmol min31 mg31 at 10‡C.
The uptake is driven by the vpH across the mito-
chondrial inner membrane. Glutamine e¥ux has also
been measured [23]. The release (at 0‡C) of
[14C]glutamine from loaded mitochondria was pre-
vented by mersalyl, whereas the e¥ux was started
by the addition of glutathione. Optimal rates are 10
nmol glutamine min31 mg protein31.
Glutamine uptake has been studied in puri¢ed rat
brain mitochondria of synaptic or non-synaptic ori-
gin [24]. Kinetic analysis showed a saturable trans-
port process with an a⁄nity two times higher in syn-
aptic than in non-synaptic mitochondria (Km 0.45
and 0.94 mM, respectively). Vmax of uptake was sev-
en times higher in synaptic mitochondria (Vmax 9.2
and 1.3 nmol min31 mg protein31, respectively). Glu-
tamine transport was found to be inhibited by L-glu-
tamate (IC50 0.64 mM) as well as thiol reagents
(mersalyl, N-ethylmaleimide). It is suggested that dif-
ferential uptake of glutamine in mitochondria of syn-
aptic or non-synaptic origin may be a major mecha-
nism in the regulation of the synthesis of the
neurotransmitter glutamate.
2.4. Arginine transport
An arginine transport system has been character-
ised in brain mitochondria [25]. Analysis of uptake
kinetics revealed a high a⁄nity component with a
mean Km of 0.08 mM, and Vmax of 1.89 nmol min-
31 mg31, and a very low a⁄nity component probably
manifesting di¡usion. The uptake of 25 mM L-argi-
nine was strongly inhibited by a 20-fold excess of L-
lysine and L-ornithine, but not by D-arginine nor any
neutral amino acid. L-arginine uptake into mitochon-
dria was also inhibited by a nitric oxide synthase
(NOS) inhibitor L-N-monomethyl arginine (L-
NMMA), but not by another NOS inhibitor NG-ni-
tro-L-arginine (L-NNA). Uptake was not signi¢cantly
a¡ected by 20-fold excess of L-histidine, L-glutamate
or L-glutamine.
3. The carnitine/acylcarnitine translocase
Long chain fatty acids are transported into the
mitochondrial matrix as acylcarnitines. Within the
matrix, carnitine palmitoyltransferase II removes
the carnitine and replaces it with a coenzyme A
(CoA), thus committing acyl-CoA molecules for L-
oxidation. The mitochondrial inner membrane con-
tains an antiporter exchange system for entry and
exit of carnitine and acylcarnitines. This transport
system in mitochondria has been extensively re-
searched by Pande and coworkers [26] and Tubbs
and [27] and has been reviewed by Bieber [28]. In
addition to exchange transport the carnitine/acylcar-
nitine translocase has the capacity for unidirectional
carnitine transport. Evidence for this has come from
experiments showing the 11-trimethylamino-undeca-
noyl-L-carnitine, a speci¢c inhibitor of the translo-
case, could also inhibit the slower (0.5% of exchange
rate) unidirectional transport of carnitine [27]. Ear-
lier studies showed a Km of 5.3 mM in heart mito-
chondria but subsequent investigations indicate a
lower apparent Km [29].
It was also shown that various acylcarnitines com-
pete for the translocase, thus acting as competitive
inhibitors of the translocase. These latter studies
showed that the branched-chain acylcarnitine, isobu-
tyrylcarnitine, has a considerably lower a⁄nity for
the translocase on the external side than acylcarnitine
or free carnitine. Both isovalerylcarnitine and octa-
noylcarnitine inhibit the translocase. The translocase
is also inhibited by both mersalyl and N-ethylmalei-
mide (NEM), which suggests the involvement of a
sulphydryl group. The competitive nature of mersalyl
suggests that a sulphydryl is involved in binding [30].
Derivatives of hydroxycinnamate which inhibit pyru-
vate transport also inhibit the translocase but at con-
centrations an order of magnitude higher [31].
Studies by LaNoue et al. [32], in which mitochon-
dria were loaded with carnitine and in which acylcar-
nitine was used as metabolic substrate, suggest that
the translocase has a minimum transport capacity of
100 nmol carnitine release min31 mg protein31. Stud-
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ies on e¥ux of acylcarnitine from mitochondria ox-
idising pyruvate show similar e¥ux rates [33]. These
studies strongly indicate that liver and heart mito-
chondria contain su⁄cient carnitine/acylcarnitine
translocase activity for it not to be rate-limiting for
carnitine-promoted processes within the mitochond-
rion. In vivo, the rate of translocase activity is also
thought to be controlled by the size of the matrix
carnitine pool. In fact Murthy and Pande [34] sug-
gest the existence of two carnitine pools, one which
equilibrates rapidly with the translocase and one
which equilibrates slowly. These conclusions are
however disputed by Lysiak et al. [33].
The carnitine/acylcarnitine translocase has been
solubilised from rat liver mitochondria and reconsti-
tuted into liposomes [35]. The transporter has a mo-
lecular mass of 32.5 kDa. The reconstituted system is
sensitive to translocase inhibitors NEM, mersalyl
and sulphobetaine as well as (+)- and (3)-octanoyl-
carnitine. The transport mechanism of the reconsti-
tuted native carnitine carrier has a Km for carnitine
on the internal side of the liposome membrane, of 8.7
mM while that of the outside was 0.45 mM. The
carnitine transporter has also been cloned [36] and
the human chromosomal site identi¢ed at band
3p21.31 [37]. The bacterially overexpressed, puri¢ed
and reconstituted transporter has a Km for carnitine
uptake of 0.47 mM, a Vmax of 0.78 mmol min31 g
protein31 of protein and a Ki for octanolylcarnitine
of 13.5 WM, virtually identical kinetics to that of the
native carrier [38].
4. The ornithine and citrulline carrier(s)
Important aspects of ornithine transport were es-
tablished by Gamble and Lehninger [12]. It was
found that ornithine transcarbamoylase and carba-
moyl phosphate synthase were located mainly in
the mitochondrial matrix, indicating that during the
urea cycle ornithine must pass from the cytosol
where it is formed to the matrix transcarbamoylase.
The product of the reaction catalysed by this enzyme
is citrulline. Since the pK of the N-amino-group of
ornithine is 10.8, at neutral pH, this molecule carries
a net positive charge. Results showed that mitochon-
dria swell when suspended in ornithine salts of ace-
tate, bicarbonate or phosphate when succinate is
added. Also, the accumulation ratio of radiolabelled
ornithine was high in the presence of phosphate and
succinate and was inhibited by respiratory inhibitors
and uncoupling agents. It was also shown that orni-
thine transport is stereoselective. D-Ornithine and the
closely related lysine and arginine could not be trans-
ported. In addition, ornithine transport occurred in
the liver mitochondria but not in heart mitochondria,
which cannot synthesise urea, indicating that trans-
port is tissue speci¢c, which provided further evi-
dence for the existence of a carrier. It was concluded
that ornithine entered mitochondria on an electro-
phoretic uniporter.
Subsequently, McGivan et al. [39] showed that the
energy dependent accumulation of ornithine ob-
served by Gamble and Lehninger [12] was due to
metabolism of the radiolabelled ornithine by orni-
thine aminotransferase present in the matrix space
and to non-speci¢c binding to the mitochondrial in-
ner membrane surface. In the presence of aminooxy-
acetate, an inhibitor of the aminotransferase, it was
shown that ornithine uptake was not in£uenced by
respiratory chain substrates or inhibitors, uncouplers
or by inhibitors of the phosphate carrier [40]. Orni-
thine uptake was shown to be a function of the pH
gradient across the mitochondrial inner membrane
with acidi¢cation of the matrix space leading to ac-
cumulation of ornithine. The results indicated the
presence of an ornithine/H antiporter. The Vmax
for ornithine uptake in isolated mitochondria was
found to be 8.3 nmol min31 mg protein31 with a
Km of 1.0 mM, measured at pH 7.2 and 20‡C. This
rate would correspond to about 120 WM/g dry wt.
per hour in liver (at 20‡C), which may be compared
with the rate of urea synthesis in isolated liver cells
(with alanine as substrate) of about 300 Wmol/g dry
wt. per hour at 37‡C [40]. It therefore appears that
the rate of ornithine uptake is at most barely ad-
equate to support the overall rate of urea synthesis,
suggesting either that the carrier may be a rate-limit-
ing step or that the calculated Vmax is too low. Data
from Saavedra-Molina and Pin‹a [41] suggest that
Ca2 ions and L-arginine modulate ornithine uptake.
Evidence has emerged for the existence of an orni-
thine/phosphate carrier in rat kidney mitochondria
[42]. Measurement of both proton movement across
the mitochondrial inner membrane and membrane
potential suggest that ornithine uptake is driven by
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a proton electrochemical gradient and the vpH-de-
pendent phosphate carrier [43]. Interestingly, it was
found that ornithine uptake is inhibited when succi-
nate or ascorbate plus tetramethylphenylenediamine
are used as energy sources.
The ornithine carrier has been puri¢ed from rat
liver mitochondria and reconstituted into liposomes
[44]. The activity of the carrier was in£uenced by the
phospholipid composition of the liposomes, increas-
ing in the presence of acidic phospholipids and de-
creasing in the presence of dioleoylphosphatidylcho-
line. In the reconstituted system the incorporated
ornithine carrier catalyzed a ¢rst-order reaction of
ornithine/ornithine or ornithine/citrulline exchange.
The maximum transport rate of external
[14C]ornithine was 3.2 mmol min31 mg protein31 at
25‡C. This value was independent of the type of sub-
strate present at the external or internal space of the
liposomes (ornithine, citrulline and lysine). The half-
saturation constant (Km) was 0.16 mM for ornithine,
1.2 mM for lysine and 3.6 mM for citrulline. The
activation energy of the ornithine/ornithine exchange
reaction was 89 kJ/mol. The rate of exchange had a
pH optimum at 8 and was inhibited by cations.
Knowledge of the yeast mitochondrial transporter
family has enabled the cloning of the mammalian
mitochondrial ornithine carrier. It has been shown
that Neurospora crassa ARG13 and Saccharomyces
cerevisiae ARG11 encode mitochondrial carrier pro-
teins that transport ornithine across the mitochon-
drial inner membrane. Probes to these transporters
were used to screen for orthologous mammalian
transporters. A gene (ORNT1) has been identi¢ed
that maps to human chromosome 13q14 and expres-
sion is high in liver. ORNT1 expression in ¢bro-
blasts, from patients with hyperammonaemia^hyper-
ornithinaemia^homocitrullinuria syndrome, was
shown to restore ornithine metabolism. The evidence
suggests that the ORNT 1 gene product codes for the
mammalian ornithine carrier [2].
Citrulline exit from mitochondria is required for
the synthesis of arginosuccinate by arginosuccinate
synthetase, a cytoplasmic enzyme that forms part
of the urea cycle. Rat liver mitochondria have been
shown to swell when suspended in high concentra-
tions of citrulline but swelling was not observed in
rat heart mitochondria [12]. Gamble and Lehninger
[12] concluded that citrulline can cross the inner mi-
tochondrial membrane of rat liver mitochondria but
not that of heart mitochondria.
Bradford and McGivan [45] demonstrated that ex-
ternal ornithine or lysine stimulated radiolabelled cit-
rulline release from preloaded mitochondria. They
concluded that mitochondria contain two carrier sys-
tems for ornithine; the ornithine/H exchanger de-
scribed previously, and a second carrier catalysing
ornithine/citrulline exchange. However, it was also
suggested that the results are consistent with a single
ornithine/citrulline plus H carrier [45] as is sug-
gested from the reconstituted system [44].
And ¢nally, a citrullinaemia (CTLN) has been
found to be associated with a gene locus to chromo-
some 7q21.3. Positional cloning was used to identify
a novel gene, SLC25A13, which encodes a 3.4-kb
transcript expressed most abundantly in liver. The
protein encoded by SLC25A13, named citrin, is bi-
partite in structure, containing a mitochondrial car-
rier motif and four EF-hand domains, suggesting it is
a calcium-dependent mitochondrial solute transport-
er with a role in urea cycle function [46].
5. The choline transporter
In mammals betaine (N,N,N-trimethyl glycine)
acts as a source of methyl groups for carbon-one
metabolism in the liver [47] and plays an essential
role as an organic osmolyte in the papilla of the
kidney [48]. The only intracellular source of betaine
is from the oxidation of choline. Choline oxidation
occurs in the matrix of mitochondria in liver and
kidney [47]. An FAD-linked choline dehydrogenase,
situated on the inner side of the inner membrane,
converts choline to betaine aldehyde, which in turn
is converted to betaine by an NAD-linked betaine
aldehyde dehydrogenase situated in the matrix.
At physiological concentrations (60^340 WM) of
choline (a cation), a speci¢c transporter for choline
is detectable and it has been characterised for liver
mitochondria. The transporter has Michaelis^Ment-
en kinetics with a Km of 220 WM (at high membrane
potentials) and a Vmax of 200 nmol min31 mg
protein31. Competitive inhibitors have been de-
scribed and include hemicholinum-3 (KiV17 WM
and quinine V13 WM) [49]. The transporter appears
to be an electrophoretic uniporter and the choline
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transport rate has a linear dependence on membrane
potential. The transporter does not exist in heart
mitochondria but preliminary investigations show a
hemicholinium-3 sensitive choline transport process
in kidney mitochondria (R.K. Porter, R. Donagh,
N. O’Donoghue, unpublished results) as might be
expected.
Betaine (a zwitterion at neutral pH), the oxidation
product of choline, appears to di¡use out of the ma-
trix, of liver mitochondria, in a concentration depen-
dent (membrane potential independent) manner as
do its analogues N,N-dimethylglycine and sarcosine
(N-methyl glycine) [50]. In metabolic control analysis
studies on isolated liver mitochondria, the choline
transporter was shown the majority (90%) of the
control over choline oxidation [51]. The transporter
has not been puri¢ed to date.
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